Page 85 - 2020年1月第31卷第2期

diabetes mellitus in pancreatic cancer compared to com- [15] WANG YW，HE SJ，FENG X，et al. Metformin：a review
mon cancers[J]. Pancreas，2013，42（2）：198-201. of its potential indications[J]. Drug Des Devel Ther，
[ 3 ] ELENA JW，STEPLOWSKI E，YU K，et al. Diabetes and 2017. DOI：10.2147/DDDT.S141675.
risk of pancreatic cancer：a pooled analysis from the pan- [16] NAIR V，PATHI S，JUTOORU I，et al. Metformin inhibits
creatic cancer cohort consortium[J]. Cancer Causes Con- pancreatic cancer cell and tumor growth and downregu-
trol，2013，24（1）：13-25. lates SP transcription factors[J]. Carcinogenesis，2013，34
[ 4 ] CHOI Y，KIM TY，OH DY，et al. The impact of diabetes （12）：2870-2879.
mellitus and metformin treatment on survival of patients [17] GONG J，ROBBINS LA，LUGEA A，et al. Diabetes，pan-
with advanced pancreatic cancer undergoing chemothera- creatic cancer，and metformin therapy[J]. Front Physiol，
py[J]. Cancer Res Treat，2016，48（1）：171-179. 2014. DOI：10.3389/fphys.2014.00426.
[ 5 ] XIN W，FANG L，FANG Q，et al. Effects of metformin on [18] DE SOUZA A，KHAWAJA KI，MASUD F，et al. Metfor-
survival outcomes of pancreatic cancer patients with dia- min and pancreatic cancer：is there a role? [J]. Cancer
betes：a meta-analysis[J]. Mol Clin Oncol，2018，8（3）： Chemother Pharmacol，2016，77（2）：235-242.
483-488. [19] INCIO J，SUBOJ P，CHIN SM，et al. Metformin reduces
[ 6 ] RENI M，DUGNANI E，CEREDA S，et al.（Ir）relevance desmoplasia in pancreatic cancer by reprogramming stel-
of metformin treatment in patients with metastatic pancre- late cells and tumor-associated macrophages[J]. PLoS
atic cancer：an open-label，randomized phase Ⅱ trial[J]. One，2015，10（12）：e0141392.
Clin Cancer Res，2016，22（5）：1076-1085. [20] NIETO MA，HUANG RY，JACKSON RA，et al. EMT：
[ 7 ] KORDES S，POLLAK MN，ZWINDERMAN AH，et al. 2016[J]. Cell，2016，166（1）：21-45.
Metformin in patients with advanced pancreatic cancer：a [21] WANG Q，QU X. New insights into the roles of RGC-
double-blind，randomised，placebo-controlled phase 2 tri- 32[J]. Cell Mol Immunol，2018，15（8）：803-804.
al[J]. Lancet Oncol，2015，16（7）：839-847. [22] ZHU L，QIN H，ZHAO Q，et al. Response gene to comple-
[ 8 ] RHIM AD，MIREK ET，AIELLO NM，et al. EMT and dis- ment-32 enhances metastatic phenotype by mediating
semination precede pancreatic tumor formation[J]. Cell， transforming growth factor beta-induced epithelial-mesen-
2012，148（1/2）：349-361. chymal transition in human pancreatic cancer cell line Bx-
[ 9 ] DERYNCK R，ZHANG YE. Smad-dependent and Smad- PC-3[J]. J Exp Clin Cancer Res，2012. DOI：10.1186/
independent pathways in TGF-beta family signalling[J]. 1756-9966-31-29.
Nature，2003，425（6958）：577-584. [23] ZHU L，DING Y，ZHAO Q. Response gene to comple-
[10] LEVY L，HILL CS. Smad4 dependency defines two class- ment-32 mediates TGF-beta-induced epithelial-mesenchy-
es of transforming growth factor β（TGF-β）target genes mal transition via Erk-p38-MAPK signaling pathways in
and distinguishes TGF-β-induced epithelial-mesenchymal human pancreatic cancer cell line BxPC-3[J]. Int J Clin
transition from its antiproliferative and migratory respons- Exp Pathol，2017，10（6）：7135-7143.
es[J]. Mol Cell Biol，2005，25（18）：8108-8125. [24] ZHU L，ZHAO Q. Hypoxia-inducible factor I alpha partic-
[11] BARDEESY N，DEPINHO RA. Pancreatic cancer biolo- ipates in hypoxia-induced epithelial-mesenchymal transi-
gy and genetics[J]. Nat Rev Cancer，2002，2（12）：897- tion vis response gene to complement 32[J]. Exp Ther
909. Med，2017，14（2）：1825-1831.
[12] WILENTZ RE，IACOBUZIO-DONAHUE CA，ARGANI [25] ZHU L，DING Y. RGC-32 induces transition of pancreatic
P，et al. Loss of expression of DPC4 in pancreatic intraepi- cancer to epithelial mesenchyme in vivo[J]. Pancreatolo-
thelial neoplasia：evidence that DPC4 inactivation occurs gy，2018，18（5）：572-576.
late in neoplastic progression[J]. Cancer Res，2000，60 [26] CUI XB，LUAN JN，YE J，et al. RGC32 deficiency pro-
（7）：2002-2006. tects against high-fat diet-induced obesity and insulin re-
[13] TONG D，LIU Q，LIU G，et al. Metformin inhibits castra- sistance in mice[J]. J Endocrinol，2015，224（2）：127-137.
tion-induced EMT in prostate cancer by repressing COX2/ [27] CUI XB，LUAN JN，CHEN SY. RGC-32 deficiency pro-
PGE2/STAT3 axis[J]. Cancer Lett，2017. DOI：10.1016/j. tects against hepatic steatosis by reducing lipogenesis[J]. J
canlet.2016.12.031. Biol Chem，2015，290（33）：20387-20395.
[14] KAMISAWA T，WOOD LD，ITOI T，et al. Pancreatic can- （收稿日期：2019-05-14 修回日期：2019-10-19）
cer[J]. Lancet，2016，388（10039）：73-85. （编辑：张元媛）

中国药房 2020年第31卷第2期 China Pharmacy 2020 Vol. 31 No. 2 ·207 ·